liver cirrhosis (Q7341568): Difference between revisions

From EU Knowledge Graph

Jump to navigation Jump to search

Revision as of 13:29, 29 December 2024 WikidataUpdater (talk | contribs) (‎Changed an Item: Adding these statements since they where added in Wikidata) ← Older edit		Revision as of 13:29, 29 December 2024 WikidataUpdater (talk | contribs) (‎Changed an Item: Adding these statements since they where added in Wikidata) Newer edit →
		Property / drug or therapy used for treatment
			bumetanide
		Property / drug or therapy used for treatment: bumetanide / rank
			Normal rank
		Property / drug or therapy used for treatment: bumetanide / reference
			stated in: NDF-RT
		Property / drug or therapy used for treatment: bumetanide / reference
			NDF-RT ID: N0000146155
		Property / drug or therapy used for treatment: bumetanide / reference
			language of work or name: English
		Property / drug or therapy used for treatment: bumetanide / reference
			retrieved: 13 December 2016 Timestamp +2016-12-13T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / drug or therapy used for treatment
			furosemide
		Property / drug or therapy used for treatment: furosemide / rank
			Normal rank
		Property / drug or therapy used for treatment: furosemide / reference
			stated in: NDF-RT
		Property / drug or therapy used for treatment: furosemide / reference
			NDF-RT ID: N0000146188
		Property / drug or therapy used for treatment: furosemide / reference
			language of work or name: English
		Property / drug or therapy used for treatment: furosemide / reference
			retrieved: 13 December 2016 Timestamp +2016-12-13T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / drug or therapy used for treatment
			ethacrynic acid
		Property / drug or therapy used for treatment: ethacrynic acid / rank
			Normal rank
		Property / drug or therapy used for treatment: ethacrynic acid / reference
			stated in: NDF-RT
		Property / drug or therapy used for treatment: ethacrynic acid / reference
			NDF-RT ID: N0000146283
		Property / drug or therapy used for treatment: ethacrynic acid / reference
			language of work or name: English
		Property / drug or therapy used for treatment: ethacrynic acid / reference
			retrieved: 13 December 2016 Timestamp +2016-12-13T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / drug or therapy used for treatment
			torasemide
		Property / drug or therapy used for treatment: torasemide / rank
			Normal rank
		Property / drug or therapy used for treatment: torasemide / reference
			stated in: NDF-RT
		Property / drug or therapy used for treatment: torasemide / reference
			NDF-RT ID: N0000148359
		Property / drug or therapy used for treatment: torasemide / reference
			language of work or name: English
		Property / drug or therapy used for treatment: torasemide / reference
			retrieved: 13 December 2016 Timestamp +2016-12-13T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / drug or therapy used for treatment
			ethacrynate sodium
		Property / drug or therapy used for treatment: ethacrynate sodium / rank
			Normal rank
		Property / drug or therapy used for treatment: ethacrynate sodium / reference
			stated in: NDF-RT
		Property / drug or therapy used for treatment: ethacrynate sodium / reference
			NDF-RT ID: N0000146284
		Property / drug or therapy used for treatment: ethacrynate sodium / reference
			language of work or name: English
		Property / drug or therapy used for treatment: ethacrynate sodium / reference
			retrieved: 13 December 2016 Timestamp +2016-12-13T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / drug or therapy used for treatment
			rifaximin
		Property / drug or therapy used for treatment: rifaximin / rank
			Normal rank
		Property / drug or therapy used for treatment: rifaximin / reference
			stated in: Drug Indications Extracted from FAERS
		Property / drug or therapy used for treatment: rifaximin / reference
			retrieved: 2 October 2018 Timestamp +2018-10-02T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / drug or therapy used for treatment
			ledipasvir/sofosbuvir
		Property / drug or therapy used for treatment: ledipasvir/sofosbuvir / rank
			Normal rank
		Property / drug or therapy used for treatment: ledipasvir/sofosbuvir / reference
			stated in: Drug Indications Extracted from FAERS
		Property / drug or therapy used for treatment: ledipasvir/sofosbuvir / reference
			retrieved: 2 October 2018 Timestamp +2018-10-02T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / drug or therapy used for treatment
			obeticholic acid
		Property / drug or therapy used for treatment: obeticholic acid / rank
			Normal rank
		Property / drug or therapy used for treatment: obeticholic acid / reference
			stated in: Drug Indications Extracted from FAERS
		Property / drug or therapy used for treatment: obeticholic acid / reference
			retrieved: 2 October 2018 Timestamp +2018-10-02T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / drug or therapy used for treatment
			sofosbuvir
		Property / drug or therapy used for treatment: sofosbuvir / rank
			Normal rank
		Property / drug or therapy used for treatment: sofosbuvir / reference
			stated in: Drug Indications Extracted from FAERS
		Property / drug or therapy used for treatment: sofosbuvir / reference
			retrieved: 2 October 2018 Timestamp +2018-10-02T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / drug or therapy used for treatment
			peginterferon alfa-2b
		Property / drug or therapy used for treatment: peginterferon alfa-2b / rank
			Normal rank
		Property / drug or therapy used for treatment: peginterferon alfa-2b / reference
			stated in: Drug Indications Extracted from FAERS
		Property / drug or therapy used for treatment: peginterferon alfa-2b / reference
			retrieved: 2 October 2018 Timestamp +2018-10-02T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / drug or therapy used for treatment
			boceprevir
		Property / drug or therapy used for treatment: boceprevir / rank
			Normal rank
		Property / drug or therapy used for treatment: boceprevir / reference
			stated in: Drug Indications Extracted from FAERS
		Property / drug or therapy used for treatment: boceprevir / reference
			retrieved: 2 October 2018 Timestamp +2018-10-02T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / drug or therapy used for treatment
			tolvaptan
		Property / drug or therapy used for treatment: tolvaptan / rank
			Normal rank
		Property / drug or therapy used for treatment: tolvaptan / reference
			stated in: Drug Indications Extracted from FAERS
		Property / drug or therapy used for treatment: tolvaptan / reference
			retrieved: 2 October 2018 Timestamp +2018-10-02T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / drug or therapy used for treatment
			daclatasvir
		Property / drug or therapy used for treatment: daclatasvir / rank
			Normal rank
		Property / drug or therapy used for treatment: daclatasvir / reference
			stated in: Drug Indications Extracted from FAERS
		Property / drug or therapy used for treatment: daclatasvir / reference
			retrieved: 2 October 2018 Timestamp +2018-10-02T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / drug or therapy used for treatment
			ribavirin
		Property / drug or therapy used for treatment: ribavirin / rank
			Normal rank
		Property / drug or therapy used for treatment: ribavirin / reference
			stated in: Drug Indications Extracted from FAERS
		Property / drug or therapy used for treatment: ribavirin / reference
			retrieved: 2 October 2018 Timestamp +2018-10-02T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / drug or therapy used for treatment
			adefovir
		Property / drug or therapy used for treatment: adefovir / rank
			Normal rank
		Property / drug or therapy used for treatment: adefovir / reference
			stated in: Drug Indications Extracted from FAERS
		Property / drug or therapy used for treatment: adefovir / reference
			retrieved: 2 October 2018 Timestamp +2018-10-02T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / drug or therapy used for treatment
			peginterferon alfa-2a
		Property / drug or therapy used for treatment: peginterferon alfa-2a / rank
			Normal rank
		Property / drug or therapy used for treatment: peginterferon alfa-2a / reference
			stated in: Drug Indications Extracted from FAERS
		Property / drug or therapy used for treatment: peginterferon alfa-2a / reference
			retrieved: 2 October 2018 Timestamp +2018-10-02T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / drug or therapy used for treatment
			simeprevir
		Property / drug or therapy used for treatment: simeprevir / rank
			Normal rank
		Property / drug or therapy used for treatment: simeprevir / reference
			stated in: Drug Indications Extracted from FAERS
		Property / drug or therapy used for treatment: simeprevir / reference
			retrieved: 2 October 2018 Timestamp +2018-10-02T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / drug or therapy used for treatment
			entecavir hydrate
		Property / drug or therapy used for treatment: entecavir hydrate / rank
			Normal rank
		Property / drug or therapy used for treatment: entecavir hydrate / reference
			stated in: Drug Indications Extracted from FAERS
		Property / drug or therapy used for treatment: entecavir hydrate / reference
			retrieved: 2 October 2018 Timestamp +2018-10-02T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / genetic association
			TSBP1
		Property / genetic association: TSBP1 / rank
			Normal rank
		Property / genetic association: TSBP1 / qualifier
			determination method: genome-wide association study
		Property / genetic association: TSBP1 / qualifier
			determination method: TAS
		Property / genetic association: TSBP1 / reference
			reference URL: https://gemma.msl.ubc.ca/phenotypes.html?phenotypeUrlId=DOID_5082&ncbiId=10665 reference URL: http://www.genome.gov/gwastudies/index.cfm?gene=C6orf10
		Property / genetic association: TSBP1 / reference
			stated in: Phenocarta stated in: A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region
		Property / genetic association: TSBP1 / reference
			retrieved: 25 May 2020 Timestamp +2020-05-25T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0
		Property / genetic association
			BTNL2
		Property / genetic association: BTNL2 / rank
			Normal rank
		Property / genetic association: BTNL2 / qualifier
			determination method: genome-wide association study
		Property / genetic association: BTNL2 / qualifier
			determination method: TAS
		Property / genetic association: BTNL2 / reference
			reference URL: https://gemma.msl.ubc.ca/phenotypes.html?phenotypeUrlId=DOID_5082&ncbiId=56244 reference URL: http://www.genome.gov/gwastudies/index.cfm?gene=BTNL2
		Property / genetic association: BTNL2 / reference
			stated in: Phenocarta stated in: A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region
		Property / genetic association: BTNL2 / reference
			retrieved: 25 May 2020 Timestamp +2020-05-25T00:00:00Z Timezone +00:00 Calendar Gregorian Precision 1 day Before 0 After 0

---

Revision as of 13:29, 29 December 2024

chronic disease of the liver, characterized by fibrosis

• cirrhosis of liver
• cirrhosis of the liver
• cirrhosis

Language	Label	Description	Also known as
English	liver cirrhosis	chronic disease of the liver, characterized by fibrosis	cirrhosis of liver cirrhosis of the liver cirrhosis

Statements

subclass of

liver disease

3 references

stated in

Disease Ontology

retrieved

30 November 2020

Disease Ontology ID

DOID:5082

cirrosis

0 references

disease

0 references

Commons category

Cirrhosis

0 references

image

Liver Cirrhosis.png
1,200 × 800; 438 KB

language of work or name

English

1 reference

imported from Wikimedia project

Dutch Wikipedia

Cirrhosis Liver 4x.jpg
2,048 × 1,536; 3.95 MB

0 references

Liver Cirrhosis es.png
1,200 × 800; 501 KB

language of work or name

Spanish

0 references

Liver Cirrhosis-it.png
1,200 × 800; 566 KB

language of work or name

Italian

0 references

Liver Cirrhosis-ar.png
1,200 × 800; 574 KB

language of work or name

Arabic

0 references

Karaciğer sirozu.png
1,200 × 800; 497 KB

language of work or name

Turkish

0 references

afflicts

human

0 references

has cause

alcoholism

0 references

hepatitis

0 references

Indian childhood cirrhosis

0 references

autoimmune hepatitis

0 references

primary sclerosing cholangitis

0 references

HFE hereditary haemochromatosis

0 references

Wilson disease

0 references

medical examination

liver biopsy

0 references

blood test

0 references

medical ultrasonography

0 references

computed tomography

0 references

health specialty

gastroenterology

0 references

hepatology

0 references

has effect

liver cancer

0 references

liver failure

0 references

NCI Thesaurus ID

C2951

3 references

stated in

Disease Ontology

retrieved

15 May 2019

Disease Ontology ID

DOID:5082

C2951

mapping relation type

exact match

3 references

stated in

Monarch Disease Ontology release 2018-06-29

retrieved

4 August 2018

Mondo ID

MONDO_0005155

drug or therapy used for treatment

bumetanide

4 references

stated in

NDF-RT

NDF-RT ID

N0000146155

language of work or name

English

retrieved

13 December 2016

furosemide

4 references

stated in

NDF-RT

NDF-RT ID

N0000146188

language of work or name

English

retrieved

13 December 2016

ethacrynic acid

4 references

stated in

NDF-RT

NDF-RT ID

N0000146283

language of work or name

English

retrieved

13 December 2016

torasemide

4 references

stated in

NDF-RT

NDF-RT ID

N0000148359

language of work or name

English

retrieved

13 December 2016

ethacrynate sodium

4 references

stated in

NDF-RT

NDF-RT ID

N0000146284

language of work or name

English

retrieved

13 December 2016

rifaximin

2 references

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

ledipasvir/sofosbuvir

2 references

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

obeticholic acid

2 references

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

sofosbuvir

2 references

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

peginterferon alfa-2b

2 references

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

boceprevir

2 references

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

tolvaptan

2 references

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

daclatasvir

2 references

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

ribavirin

2 references

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

adefovir

2 references

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

peginterferon alfa-2a

2 references

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

simeprevir

2 references

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

entecavir hydrate

2 references

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

genetic association

TSBP1

determination method

genome-wide association study

TAS

3 references

reference URL

https://gemma.msl.ubc.ca/phenotypes.html?phenotypeUrlId=DOID_5082&ncbiId=10665

http://www.genome.gov/gwastudies/index.cfm?gene=C6orf10

stated in

Phenocarta

A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region

retrieved

25 May 2020

BTNL2

determination method

genome-wide association study

TAS

3 references

reference URL

https://gemma.msl.ubc.ca/phenotypes.html?phenotypeUrlId=DOID_5082&ncbiId=56244

http://www.genome.gov/gwastudies/index.cfm?gene=BTNL2

stated in

Phenocarta

A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region

retrieved

25 May 2020

Identifiers

Wikidata QID

Q147778

0 references

BNCF Thesaurus ID

20788

1 reference

stated in

Nuovo soggettario

ICD-9 ID

571

1 reference

imported from Wikimedia project

English Wikipedia

eMedicine ID

185856

1 reference

imported from Wikimedia project

English Wikipedia

366426

1 reference

imported from Wikimedia project

English Wikipedia

DiseasesDB

2729

1 reference

imported from Wikimedia project

English Wikipedia

MedlinePlus ID

000255

1 reference

imported from Wikimedia project

English Wikipedia

National Diet Library ID

00564898

0 references

Freebase ID

/m/097ns

2 references

stated in

Freebase Data Dumps

publication date

28 October 2013

Patientplus ID

cirrhosis-pro

1 reference

reference URL

http://www.patient.co.uk/patientplus/c.htm

NSK ID

000237193

0 references

internetmedicin.se ID

2396

1 reference

imported from Wikimedia project

Swedish Wikipedia

Disease Ontology ID

DOID:5082

3 references

stated in

Disease Ontology

retrieved

30 November 2020

Disease Ontology ID

DOID:5082

 

Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q7341568&oldid=44975475"